we need to correct the math - it is 25,000 patients. we should be measuring the number of adverse reactions with the number of doses, not patients. if it is (over) 25,000 patients who received a dose of "O" once per month that is 100,000 doses. Even 100 adverse reactions would be 1 in 1,000. The fatality rate, on the other hand, should probably be measured on the total patient count.
That's why FDA has not imposed a recall on Omontys. It's the inexperience of the management on this drug. They should hire Amgen's medical director to be in charge of administration of the drug. Epogen has huge side effects but they know how to apply anti-hypersensitivity drug to patients and injecting Iron to patients when needed,